Food and Drug Administration Commissioner Marty Makary resigned Tuesday, stepping down before President Donald Trump could fire him over multiple policy clashes that infuriated both the White House and congressional Republicans.

E-Cigarette Battle Triggers Resignation

The New York Times reported that Makary’s resignation stemmed from his opposition to the Trump administration’s decision to permit fruit-flavored e-cigarettes. An FDA official confirmed Makary objected to the policy reversal, which contradicted his public health stance on protecting youth from vaping products. His departure marks the latest clash between career health officials and Trump’s regulatory agenda, particularly on issues affecting consumer choice and personal freedom.

Republicans Criticize Abortion Drug Inaction

Congressional Republicans had attacked Makary for failing to deliver on his promise to review the safety of mifepristone, the abortion medication. Trump and GOP lawmakers pushed the FDA to reverse Biden-era rules allowing doctors to prescribe the drug through telemedicine appointments. The commissioner faced mounting pressure from conservatives who expected swift action on restricting abortion access through federal regulatory channels. His reluctance to act quickly on this priority issue eroded support among Trump allies.

Controversial Decisions Anger Health Community

Makary drew criticism from multiple directions during his brief tenure. The FDA released an unsupported memo claiming COVID-19 vaccine-related deaths, sparking backlash from medical professionals. He also loosened restrictions on peptides, unproven compounds championed by Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again movement. Diana Zuckerman from the National Center for Health Research noted Makary managed to offend nearly everyone involved in FDA decisions, though she warned his replacement could be worse if chosen to please tobacco companies or anti-abortion activists.

What This Means

The resignation highlights ongoing tensions between the Trump administration’s deregulatory approach and traditional FDA safety protocols. Makary’s departure creates uncertainty about the agency’s future direction on critical issues including drug approvals, tobacco regulation, and vaccine oversight. His replacement will face immediate pressure to align with White House priorities while maintaining the FDA’s scientific credibility and protecting public health standards that many Americans rely upon for safe food and medicine.